Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The North American Prodromal Synucleinopathy (NAPS) Consortium: Baseline Neuropsychological Findings in 70 Participants
Aging, Dementia, and Behavioral Neurology
P15 - Poster Session 15 (12:00 PM-1:00 PM)
10-007
To present initial neuropsychological data on 70 participants with REM sleep behavior disorder (RBD) without a clinical diagnosis of dementia who are in the North American Prodromal Synucleinopathy (NAPS) Consortium.
It is important to determine the natural history of individuals with RBD and generate clinical and neuropsychological data for planning disease-modifying trials to delay or prevent phenoconversion of RBD to an overt synucleinopathy such as dementia with Lewy bodies, Parkinson’s disease, or multiple system atrophy.
As part of the NAPS protocol (www.naps-rbd.org), investigators at 7 centers in North America are enrolling a target of 300 participants with RBD. A comprehensive clinical battery and a set of neuropsychological measures (using the National Alzheimer Coordinating Center Uniform Data Set version 3 or UDS3) are performed at each visit.
Participants were 77% male (n=54), ranging in age from 39-85 (Mean=66.9, SD=9.48) and education from 10-20 years (Mean=16.5, SD=2.49).  Eight participants (11%) were impairment-free across all tests administered. Numbers of participants (%) with impaired scores were tabulated as follows (< -1.5 SD and < -2 SD, respectively, after adjustment for age, sex, and education): global cognition, 13 (19%) and 12 (17%); attention/executive functioning, 24 (34%) and 14 (20%); language, 27 (39%) and 12 (17%); visuospatial, 15 (21%) and 9 (13%); and learning/memory, 30 (43%) and 13 (19%).
Collection of a comprehensive set of clinical and neuropsychological measures is feasible and tolerated in RBD patients. Using the UDS3 neuropsychological test battery, impairment in one or more measures was present in 89% of participants, and 53% showed impairments greater than 2 SD below the mean in the absence of a clinical diagnosis of dementia. Future longitudinal assessments will be required to determine the predictive utility of neuropsychological performance for phenoconversion of RBD to an overt synucleinopathy.
Authors/Disclosures
Julie A. Fields, PhD (Mayo Clinic)
PRESENTER 		The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Bradley F. Boeve, MD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Leah K. Forsberg, PhD (Mayo Clinic) Ms. Forsberg has nothing to disclose.
Erik K. St. Louis, MD (Mayo Clinic) The institution of Dr. St. Louis has received research support from NIH. Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. St. Louis has received publishing royalties from a publication relating to health care.
No disclosure on file
Kevin R. Nelson, MD, FÂ鶹´«Ã½Ó³»­ (University of Kentucky) No disclosure on file
No disclosure on file
No disclosure on file
Alon Y. Avidan, MD, MPH, FÂ鶹´«Ã½Ó³»­ (David Geffen School of Medicine at UCLA) Dr. Avidan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Avidan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avadel. Dr. Avidan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Harmony. Dr. Avidan has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. Dr. Avidan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Avidan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Harmony. Dr. Avidan has received publishing royalties from a publication relating to health care.
No disclosure on file
Ronald Postuma, MD (Montreal General Hospital) Dr. Postuma has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche, Biogen, Takeda, Theranexus, GE, Jazz, Curasen, Paladin, Inception Sciences, Phytopharmics, Vaxxinity, Merck. Dr. Postuma has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen/Partners. The institution of Dr. Postuma has received research support from CIHR, Weston Foundation, Webster Foundation, Roche, MJFF, Parkinson Canada, FRSQ, NIH.
Amelie Pelletier (Montreal General Hospital) Ms. Pelletier has nothing to disclose.
Michael J. Howell, MD, FÂ鶹´«Ã½Ó³»­ The institution of Dr. Howell has received research support from National Institutes of Health. Dr. Howell has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Rebekah L. Summers, PhD, PT (Medtronic) Rebekah Summers has received personal compensation for serving as an employee of Medtronic. Rebekah Summers has received research support from National Institute of Health.
No disclosure on file
Daniel Huddleston, MD (Emory University) The institution of Dr. Huddleston has received research support from NIH-NINDS 1K23NS105944-01A1. The institution of Dr. Huddleston has received research support from Michael J. Fox Foundation (MJFF-010556). The institution of Dr. Huddleston has received research support from Lewy Body Dementia Association Research Center of Excellence (Emory). The institution of Dr. Huddleston has received research support from American Parkinson's Disease Association.
No disclosure on file
No disclosure on file
Aleksandar Videnovic, MD, MSc, FÂ鶹´«Ã½Ó³»­ (MGH Neurological Clinical Research Institute) Dr. Videnovic has nothing to disclose.
No disclosure on file
No disclosure on file
Walter A. Kukull, PhD, FÂ鶹´«Ã½Ó³»­ (Washington University of Medicine) The institution of Dr. Kukull has received research support from NIH/NIA. Dr. Kukull has a non-compensated relationship as a Associate editor with Alzheimer's and Dementia TRCI (journal) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Kukull has a non-compensated relationship as a Editorial board with Journal of American Geriatrics Soc that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Jennifer S. McLeland (Washington University School of Medicine) Ms. McLeland has nothing to disclose.
Yo-El Ju, MD The institution of Dr. Ju has received research support from National Institutes of Health.